GlobalMed Technologies USA has launched its own crowdfunding platform under Regulation D, Rule 506(c), solely directed to accredited Investors. We are leaders in the development of Photonic biomedical technologies, systems, machinery, products and multiple applications. GMT seeks to expand their outreach of its proprietary Photonic Corpuscular Irradiation (“PCI”) biomedical treatment system which will innovate and advance the frontiers of medical scientific inquiry and medical treatments as we know it.
Our platform has already been used in several clinical studies that we have performed on both humans and animals. The Goal is to complete the development and bring to market, potential biomedical applications (cost efficient medical treatments) that address the significant diseases that are currently afflicting both humans and animals ( COVID19 and all its strains, HIV, Hepatitis, Swine Flu, Zika, Ebola, Malaria, Influenza virus and all its strains, Lymes, Laminitis, Parvovirus and the everyday common cold etc…).
GMT is in the process of completing several studies that include a Phase I study in the United States for Subjects that are Confirmed to Have COVID19 and Phase(s)II through IV (specific disease targeted medical clinical trials in Colombia), further documenting the efficacy of our biomedical technologies, applications and medical treatments that will essentially establish worldwide success and unprecedented results while reducing the current cost of medical treatment on Pathogens across the board by Ninety Percent (90%) for patients that are either resistant and or intolerant to retroviral regimens. Upon Completion of our promulgated clinical trials, GMT will remain as an advanced research and development (R&D) arm in the Biomedical Industry Worldwide in addition to operating as an OEM manufacturer, providing its products and service directly to the medical community Worldwide.
For further information, please leave us a comment below or send an email directly to Dr Danilo Fernandez: